# Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy

> **NCT04889430** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 34 (actual)

## Conditions studied

- Atypical Hemolytic Uremic Syndrome

## Interventions

- **DRUG:** Iptacopan

## Key facts

- **NCT ID:** NCT04889430
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-17
- **Primary completion:** 2026-04-11
- **Final completion:** 2026-04-11
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04889430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04889430, "Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04889430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*